跳至主要内容
临床试验/PACTR202407793260730
PACTR202407793260730已完成1 期

Breakthrough in Ascaris lumbricoid Treatment: Single-Dose Albendazole Proves Effective in Ethiopian School children

未提供0 个研究点目标入组 150 人开始时间: 2024年7月16日最近更新:

试验速览

阶段
1 期
状态
已完成
入组人数
150

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
6 Year(s) 至 12 Year(s)(—)
性别
All

入选标准

  • All school children whose ages ranged from 7-14 years old attending and who had microscopically confirmed A. lumbricoid mono-infection without history of anti-helminthic drugs in take within the last 6 months before study period and able to to provide required stool samples at the baseline, after 2- 3 weeks and 3 months of baseline albendazole treatment were included in the study

排除标准

  • School-age children unable to bring parents/legal guardian to the school, who have a history of known major systemic or chronic illnesses, malnutrition, and GIT diseases, who take anti-in?ammatory drugs/ antibiotics during the study period based on vital signs and prior clinical history, who have been vomiting within 4 hours after drug administration, experienced diarrhea , severe allergic reaction to albendazole, Infected with other than intestinal parasite than A.lumbricoide were excluded from the study

研究者

发起方
未提供

相似试验